Piper Sandler analyst Biren Amin reiterated an Overweight rating and $875.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments